Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Seizure, Dysgenesis of the hippocampus, Severe intellectual disability, and Pachygyria and others; and very common findings: Hypoplasia of the brainstem, Hypoplasia of the pons, and Delayed ability to walk. 34 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 13 | Bilateral tonic-clonic seizure, Hypoplasia of the brainstem, Seizure |
MACF1 encodes microtubule actin crosslinking factor 1 (7,388 aa). F-actin-binding protein which plays a role in cross-linking actin to other cytoskeletal proteins and also binds to microtubules. Highest expression in Lung (65.0 TPM) and Artery Tibial (50.4 TPM).
Lissencephaly 9 with complex brainstem malformation is associated with mutations in the MACF1 gene on chromosome 1.
The MACF1 protein participates in p-BRAF(1-380)-MACF1(600-7388) fusion pathway.
MACF1 is classified as a druggable target with score 0.0.
Genetic testing for MACF1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 7 always present features, 3 very common features, 11 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for lissencephaly 9 with complex brainstem malformation.
7 publications have been identified in PubMed for lissencephaly 9 with complex brainstem malformation. Research spans Case Report / Case Series (29%), Epidemiology / Natural History (29%), and Review / Meta-Analysis (14%).
Hwang S (2026). [PMID: 41152456](https://pubmed.ncbi.nlm.nih.gov/41152456/). *J Hum Genet*. [Review / Meta-Analysis]
Xi J (2026). [PMID: 41629993](https://pubmed.ncbi.nlm.nih.gov/41629993/). *Hum Genomics*. [Case Report / Case Series]
Kava H (2025). [PMID: 40083435](https://pubmed.ncbi.nlm.nih.gov/40083435/). *Front Pediatr*. [Epidemiology / Natural History]
Bazazzadegan N (2025). [PMID: 40001331](https://pubmed.ncbi.nlm.nih.gov/40001331/). *Arch Iran Med*. [Case Report / Case Series]
Lei XY (2025). [PMID: 40350249](https://pubmed.ncbi.nlm.nih.gov/40350249/). *J Med Genet*. [Gene Therapy / Novel Therapeutics]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 11:55 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Eyes |
2 |
Strabismus, Cerebral visual impairment |
Digestive system | 2 | Difficulty swallowing (dysphagia), Feeding difficulties |
Growth and development | 1 | Short stature |
Muscles | 1 | Low muscle tone (hypotonia) |
Heart and blood vessels | 1 | Ventricular septal defect |
Head and neck | 1 | Microcephaly |
Chenyue Z (2025). [PMID: 40603987](https://pubmed.ncbi.nlm.nih.gov/40603987/). *Sci Rep*. [Epidemiology / Natural History]